Ferguson Wellman Capital Management Inc. Has $1.78 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Ferguson Wellman Capital Management Inc. lessened its holdings in Edwards Lifesciences Co. (NYSE:EW) by 4.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,959 shares of the medical research company’s stock after selling 1,215 shares during the period. Ferguson Wellman Capital Management Inc.’s holdings in Edwards Lifesciences were worth $1,779,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of EW. Crewe Advisors LLC bought a new position in shares of Edwards Lifesciences in the 1st quarter valued at $28,000. First Community Trust NA bought a new position in Edwards Lifesciences in the second quarter valued at about $29,000. Riverview Trust Co bought a new position in Edwards Lifesciences in the first quarter valued at about $34,000. Webster Bank N. A. acquired a new stake in shares of Edwards Lifesciences during the second quarter valued at about $39,000. Finally, Peoples Bank KS bought a new stake in shares of Edwards Lifesciences during the third quarter worth about $40,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now owns 29,333 shares in the company, valued at $2,051,843.35. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,101,530.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 16,250 shares of company stock worth $1,099,238 in the last ninety days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $70.27 on Friday. The firm has a market capitalization of $42.34 billion, a P/E ratio of 30.29, a P/E/G ratio of 2.83 and a beta of 1.13. The firm’s 50-day moving average price is $67.81 and its 200-day moving average price is $79.18. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The business had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. During the same period in the prior year, the business earned $0.66 EPS. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on EW. Canaccord Genuity Group dropped their price objective on shares of Edwards Lifesciences from $77.00 to $66.00 and set a “hold” rating for the company in a report on Monday, October 7th. TD Cowen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their price target for the company from $100.00 to $70.00 in a research note on Thursday, July 25th. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 25th. JPMorgan Chase & Co. lowered Edwards Lifesciences from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $105.00 to $72.00 in a research report on Thursday, July 25th. Finally, Daiwa Capital Markets raised Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a report on Wednesday, July 31st. Fifteen analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $75.81.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.